Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

Propionyl-L-carnitine . hydrochloride [119793-66-7]

Research Use Only
AG-CR1-3595
AdipoGen Life Sciences
CAS Number119793-66-7
Product group Chemicals
Estimated Purity>98%
Molecular Weight217.3 . 36.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Propionyl-L-carnitine . hydrochloride [119793-66-7]
  • Delivery Days Customer
    10
  • CAS Number
    119793-66-7
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C10H19NO4 . HCl
  • Molecular Weight
    217.3 . 36.5
  • Scientific Description
    Chemical. CAS: 119793-66-7. Formula: C10H19NO4 . HCl. MW: 217.3 . 36.5. Synthetic. Naturally occurring carnitine derivative formed by carnitine acetyltransferase during beta-oxidation of uneven chain fatty acids, with high affinity for muscular carnitine transferase. Increases cellular carnitine content, allowing free fatty acid transport into the mitochondria. Stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activity. Important for mitochondrial metabolism and energy regulation. Regulates the metabolism of both carbohydrates and lipids, leading to an increase of ATP generation. Selectively inhibits in vitro and ex vivo platelet-activating factor (PAF) synthesis from human neutrophils. Antioxidant. Shows free radical scavenging activity. Decreases the expression of inducible nitric oxide synthase (iNOS/NOS II) and NADPH-oxidase 4-mediated reactive oxygen species production in human umbilical vascular endothelial cells. Shows beneficial cardiovascular effects. Improves body weight, food intake, adiposity and insulin resistance in Type 2 diabetes. Stimulates endothelial nitric oxide (eNOS/NOS III) and increased NO production, via AMPK/Src-mediated signaling that leads to activation of PI3 kinase and Akt. - Naturally occurring carnitine derivative formed by carnitine acetyltransferase during beta-oxidation of uneven chain fatty acids, with high affinity for muscular carnitine transferase. Increases cellular carnitine content, allowing free fatty acid transport into the mitochondria [1, 5]. Stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activity [1, 2]. Important for mitochondrial metabolism and energy regulation. Regulates the metabolism of both carbohydrates and lipids, leading to an increase of ATP generation [9, 11]. Selectively inhibits in vitro and ex vivo platelet-activating factor (PAF) synthesis from human neutrophils [3]. Antioxidant. Shows free radical scavenging activity [4]. Decreases the expression of inducible nitric oxide synthase (iNOS/NOS II) and NADPH-oxidase 4-mediated reactive oxygen species production in human umbilical vascular endothelial cells [7]. Shows beneficial cardiovascular effects. Improves body weight, food intake, adiposity and insulin resistance in Type 2 diabetes [5, 6, 8-10]. Stimulates endothelial nitric oxide (eNOS/NOS III) and increased NO production, via AMPK/Src-mediated signaling that leads to activation of PI3 kinase and Akt [6, 12].
  • SMILES
    CC[C@@H](CC(O)=O)OC(=O)CC
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine: G. Brevetti, et al.; Muscle Nerve 20, 1115 (1997)
  • Propionyl-L-carnitine: L.R. Wiseman & R.N. Brogden; Drugs Aging 12, 243 (1998) (Review)
  • Inhibition of platelet-activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine: M. Triggiani, et al.; Biochem. Pharmacol. 58, 1341 (1999)
  • L-propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector: A. Vanella, et al.; Cell Biol. Toxicol. 16, 99 (2000)
  • Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review: R. Ferrari, et al.; Ann. N. Y. Acad. Sci. 1033, 79 (2004) (Review)
  • Oral supplementation of propionyl-l-carnitine reduces body weight and hyperinsulinaemia in obese Zucker rats: C. Mingorance, et al.; Br. J. Nutr. 102, 1145 (2009)
  • Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production: M.A. Stasi, et al.; Arterioscler. Thromb. Vasc. Biol. 30, 426 (2010)
  • Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders: C. Mingorance, et al.; Vasc. Health Risk Manag. 7, 169 (2011)
  • Pharmacological effects and clinical applications of propionyl-L-carnitine: C. Mingorance, et al.; Nutr. Rev. 69, 279 (2011) (Review)
  • Propionyl-L-carnitine corrects metabolic and cardiovascular alterations in diet-induced obese mice and improves liver respiratory chain activity: C. Mingorance, et al.; PLoS One 7, e34268 (2012)